Article
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Annals of surgery - 1 Oct 2012
Andreou Andreas, Kopetz Scott, Maru Dipen M, Chen Su S, Zimmitti Giuseppe, Brouquet Antoine, Shindoh Junichi, Curley Steven A, Garrett Christopher, Overman Michael J, Aloia Thomas A, Vauthey Jean-Nicolas
Abstract excerpt
OBJECTIVE: We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC). BACKGROUND: It is unclear whether patients treated with liver resection for metachronous CLM after adjuvant FOLFOX for CRC have worse outcomes than those who received 5-FU...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.